Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 10/2020

01-10-2020 | Multiple Myeloma | Original Article

Problem Management Plus in the treatment of mental disorders in patients with multiple myeloma

Authors: Hong Zhang, Dongxiu Zhang, Hailong Lin, Leting Huang

Published in: Supportive Care in Cancer | Issue 10/2020

Login to get access

Abstract

Objectives

In this study, Problem Management Plus (PM+) was used for patients with multiple myeloma (MM), to develop a care model of psychology and quality of life.

Methods

Forty cases received psychological management (PM+ group), and 40 cases underwent investigation without management (non-PM+ group). Patients were assessed using PSYCHLOPS, WHO DAS 2.0, and HADS (see Supplementary File 1).

Results

The results showed that the PM+ group showed reductions in Psychological Outcome Profile scores (6.3 ± 2.9) following program completion (preprogram scores: 16.0 ± 1.9, P < .05). The non-PM+ group showed differences between preprogram (16.7 ± 1.8) and postprogram scores (14.8 ± 2.6, P < .05). The effect size of the PM+ group exceeded that of the non-PM+ group (5.1 to 1.0). In the Hospital Anxiety and Depression Scale, the PM+ group showed reductions in anxiety (6.4 ± 1.8) and depression (5.4 ± 0.7) (preprogram scores: 14.7 ± 4.3, P < .05 and 10.9 ± 2.6, P < .05, respectively). In the Hospital Anxiety and Depression Scale, scores for mobility, self-care, getting along, life activities, and participation decreased in the PM+ group following program completion (all P’s < .05) but did not decrease in the non-PM+ group (all P > .05).

Conclusion

The PM+ strategy could help patients to alleviate symptoms of anxiety and depression and strengthen social support, to aid in the management of problems and improve mental disorders.

Impact statement

MM patients often experienced mental disorders and wished to participate in psychosocial interventions; the PM+ strategies should be as a wide to help patients manage their problems and alleviate the symptoms of anxiety and depression.
Appendix
Available only for authorised users
Literature
1.
Kehrer M, Koob S, Strauss A, Wirtz DC, Schmolders J(2017). Multiple myeloma - current status in diagnostic testing and therapy.​ Z Orthop Unfall, 5, 575–586
2.
Eslick R, Talaulikar D(2013). Multiple myeloma: from diagnosis to treatment.​ Aust Fam Physician, 10, 684–688
3.
Reisenbuckler C(2014). Multiple myeloma and diagnostic imaging.​ Radiol Technol, 85(4), 391–410PubMed
4.
5.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV(2014). International myeloma working group updated criteria for the diagnosis of multiple myeloma.​ Lancet Oncol, 15:e538–e548PubMedCrossRef
6.
Wang Z-Y, Liu L, Shi M, Wang L(2015). Exploring correlations between positive psychological resources and symptoms of psychological distress among hematological cancer patients: a cross-sectional study.​ World Psychiatry, 14(3):354–357CrossRef
7.
Zabora J, Buzaglo J, Kennedy V, Richards T, Schapmire T, Zebrack B (2015) Clinical perspective: linking psychosocial care to the disease continuum in patients with multiple myeloma. Palliat Support Care 13(4):829–838PubMedCrossRef
8.
Rood JA, Eeltink CM, van Zuuren FJ, Verdonck-de Leeuw IM, Huijgens PC (2015) Perceived need for information of patients with haematological malignancies: a literature review. J Clin Nurs 24(3–4):353–369PubMedCrossRef
9.
Matzka M, Mayer H, Köck-Hódi S, Moses-Passini C, Dubey C, Jahn P (2016) Relationship between resilience, psychological distress and physical activity in cancer patients: a cross-sectional observation study. PLoS One 11:e0154496PubMedPubMedCentralCrossRef
10.
Dawson KS, Bryant RA, Harper M, Kuowei Tay A, Rahman A, Schafer A(2015). Problem Management Plus (PM+): a WHO transdiagnostic psychological intervention for common mental health problems.​ World Psychiatry, 14(3):354–357PubMedPubMedCentralCrossRef
11.
Rahman A, Riaz N, Dawson KS, Usman Hamdani S, Chiumento A, Sijbrandij M, Minhas F(2016). Problem Management Plus (PM+): pilot trial of a WHO transdiagnostic psychological intervention in conflict-affected Pakistan.​ World Psychiatry,15(2):182-183PubMedPubMedCentralCrossRef
12.
Sijbrandij M, Bryant RA, Schafer A, Dawson KS, Anjuri D, Ndogoni L (2014). Problem Management Plus (PM+) in the treatment of common mental disorders in women affected by gender-based violence and urban adversity in Kenya; study protocol for a randomized controlled trial.​ Asian Pac J Cancer Prev, 15(20):8855–8859CrossRef
13.
Czachowski S, Seed P, Schofield P, Ashworth M(2011). Measuring psychological change during cognitive behaviour therapy in primary care: a polish study using ‘PSYCHLOPS’ (psychological outcome profiles).​ PLoS One, 6(12):e27378PubMedPubMedCentralCrossRef
14.
Federici S, Bracalenti M, Meloni F, Luciano JV(2017). World Health Organization disability assessment schedule 2.0: an international systematic review.​ Disabil Rehabil, 39(23):2347–2380PubMedCrossRef
15.
Sangraula M, Van't Hof E, Luitel NP, Turner EL, Marahatta K, Nakao JH (2018) Protocol for a feasibility study of group-based focused psychosocial support to improve the psychosocial well-being and functioning of adults affected by humanitarian crises in Nepal: group Problem Management Plus (PM+). Pilot Feasibility Stud 18(4):126CrossRef
16.
Sales CM, Neves IT, Alves PG, Ashworth M (2018) Capturing and missing the patient’s story through outcome measures: a thematic comparison of patient-generated items in PSYCHLOPS with CORE-OM and PHQ-9. Health Expect 21(3):615–619PubMedCrossRef
17.
Swash B, Hulbert-Williams N, Bramwell R (2014) Unmet psychosocial needs in haematological cancer: a systematic review. Support Care Cancer 22(4):1131–1141PubMedCrossRef
18.
Clinton-McHarg T, Carey M, Sanson-Fisher R, Tzelepis F, Bryant J, Williamson A (2014) Anxiety and depression among haematological cancer patients attending treatment centres: prevalence and predictors. J Affect Disord 165:176–181PubMedCrossRef
19.
Korszun A, Sarker SJ, Chowdhury K, Clark C, Greaves P, Johnson R (2014) Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors. Br J Haematol 164(6):790–803PubMedCrossRef
20.
Sijbrandij M, Farooq S, Bryant RA, Dawson K, Hamdani SU, Chiumento A (2018) Correction to: Problem Management Plus (PM+) for common mental disorders in a humanitarian setting in Pakistan; study protocol for a randomised controlled trial (RCT). BMC Psychiatry 18(1):331PubMedPubMedCentralCrossRef
21.
Sijbrandij M, Bryant RA, Schafer A, Dawson KS, Anjuri D, Ndogoni L (2018) Correction to: Problem Management Plus (PM+) in the treatment of common mental disorders in women affected by gender-based violence and urban adversity in Kenya; study protocol for a randomized controlled trial. Int J Ment Health Syst 12:55PubMedPubMedCentralCrossRef
22.
Armes J, CroweM CL, Morgan H, Murrells T, Oakley C (2009) Patients’ supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey. J Clin Oncol 27(36):6172–6179PubMedCrossRef
23.
Turecki G, Ota VK, Belangero SI, Jackowski A, Kaufman J (2014) Early life adversity, genomic plasticity, and psychopathology. Lancet Psychiatry 1(6):461–466PubMedPubMedCentralCrossRef
24.
Nusslock R, Miller GE (2016) Early-life adversity and physical and emotional health across the lifespan: a neuroimmune network hypothesis. Biol Psychiatry 80(1):23–32PubMedCrossRef
25.
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122–1128PubMedCrossRef
Metadata
Title
Problem Management Plus in the treatment of mental disorders in patients with multiple myeloma
Authors
Hong Zhang
Dongxiu Zhang
Hailong Lin
Leting Huang
Publication date
01-10-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-05289-9

Other articles of this Issue 10/2020

Supportive Care in Cancer 10/2020 Go to the issue

Original Article

Let us talk about death: gender effects in cancer patients’ preferences for end-of-life discussions

Original Article

Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin

Original Article

Symptom burden among Northern Alberta radiotherapy patients with advanced cancer: mapping needs and gaps

Original Article

Exploring the role of oral microorganisms in the pathogenesis of mucositis by assessing their impact on metabolic activity and reproductive capacity of epithelial cells in vitro

Review Article

The health care cost of palliative care for cancer patients: a systematic review

Original Article

Knowledge and self-efficacy for caring for breast and colon cancer survivors among safety net primary care providers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits